

*Filed Date:* 9/15/25.  
*Accession Number:* 20250915–5051.  
*Comment Date:* 5 p.m. ET 10/6/25.  
*Docket Numbers:* ER25–3427–000.  
*Applicants:* Granite Mountain BESS East LLC.  
*Description:* 205(d) Rate Filing: Market-Based Rate Application and Request for Waivers and Blanket Approvals to be effective 11/15/2025.  
*Filed Date:* 9/15/25.  
*Accession Number:* 20250915–5053.  
*Comment Date:* 5 p.m. ET 10/6/25.  
*Docket Numbers:* ER25–3428–000.  
*Applicants:* Commonwealth Edison Company.  
*Description:* 205(d) Rate Filing: ComEd True-up, XBRL and Ministerial Revisions to Attachment H–13A to be effective 1/1/2026.  
*Filed Date:* 9/15/25.  
*Accession Number:* 20250915–5060.  
*Comment Date:* 5 p.m. ET 10/6/25.  
*Docket Numbers:* ER25–3429–000.  
*Applicants:* Harrison Renewable Energy, LLC.  
*Description:* 205(d) Rate Filing: HRE Initial MBR Application Filing to be effective 9/22/2025.  
*Filed Date:* 9/15/25.  
*Accession Number:* 20250915–5061.  
*Comment Date:* 5 p.m. ET 10/6/25.  
*Docket Numbers:* ER25–3430–000.  
*Applicants:* Midcontinent Independent System Operator, Inc., Republic Transmission, LLC.  
*Description:* 205(d) Rate Filing: Republic Transmission, LLC submits tariff filing per 35.13(a)(2)(iii): 2025–09–15\_Republic Transmission Request for Incentives to be effective 11/15/2025.  
*Filed Date:* 9/15/25.  
*Accession Number:* 20250915–5069.  
*Comment Date:* 5 p.m. ET 10/6/25.  
*Docket Numbers:* ER25–3431–000.  
*Applicants:* Mammoth Central LLC.  
*Description:* Initial Rate Filing: Baseline new to be effective 12/15/2025.  
*Filed Date:* 9/15/25.  
*Accession Number:* 20250915–5086.  
*Comment Date:* 5 p.m. ET 10/6/25.  
*Docket Numbers:* ER25–3432–000.  
*Applicants:* Mammoth Central II LLC.  
*Description:* Initial Rate Filing: Baseline new to be effective 12/15/2025.  
*Filed Date:* 9/15/25.  
*Accession Number:* 20250915–5088.  
*Comment Date:* 5 p.m. ET 10/6/25.  
*Docket Numbers:* ER25–3433–000.  
*Applicants:* TransWest Express LLC.  
*Description:* 205(d) Rate Filing: 2025–09–15 TransWest Transmission Owner Tariff Filing and Request for Waiver to be effective 12/31/9998.  
*Filed Date:* 9/15/25.  
*Accession Number:* 20250915–5089.  
*Comment Date:* 5 p.m. ET 10/6/25.

*Docket Numbers:* ER25–3434–000.  
*Applicants:* Mammoth South LLC.  
*Description:* Initial Rate Filing: Baseline new to be effective 12/15/2025.  
*Filed Date:* 9/15/25.  
*Accession Number:* 20250915–5090.  
*Comment Date:* 5 p.m. ET 10/6/25.  
*Docket Numbers:* ER25–3435–000.  
*Applicants:* Duke Energy Carolinas, LLC.  
*Description:* 205(d) Rate Filing: DEC—Decommissioning filing to be effective 11/15/2025.  
*Filed Date:* 9/15/25.  
*Accession Number:* 20250915–5114.  
*Comment Date:* 5 p.m. ET 10/6/25.  
 The filings are accessible in the Commission's eLibrary system (<https://elibrary.ferc.gov/idmws/search/fercgensearch.asp>) by querying the docket number.

Any person desiring to intervene, to protest, or to answer a complaint in any of the above proceedings must file in accordance with Rules 211, 214, or 206 of the Commission's Regulations (18 CFR 385.211, 385.214, or 385.206) on or before 5:00 p.m. Eastern Time on the specified comment date. Protests may be considered, but intervention is necessary to become a party to the proceeding.

eFiling is encouraged. More detailed information relating to filing requirements, interventions, protests, service, and qualifying facilities filings can be found at: <http://www.ferc.gov/docs-filing/efiling/filing-req.pdf>. For other information, call (866) 208–3676 (toll free). For TTY, call (202) 502–8659.

The Commission's Office of Public Participation (OPP) supports meaningful public engagement and participation in Commission proceedings. OPP can help members of the public, including landowners, community organizations, Tribal members and others, access publicly available information and navigate Commission processes. For public inquiries and assistance with making filings such as interventions, comments, or requests for rehearing, the public is encouraged to contact OPP at (202) 502–6595 or [OPP@ferc.gov](mailto:OPP@ferc.gov).

Dated: September 15, 2025.

**Carlos D. Clay,**

*Deputy Secretary.*

[FR Doc. 2025–18054 Filed 9–17–25; 8:45 am]

**BILLING CODE 6717–01–P**

## EQUAL EMPLOYMENT OPPORTUNITY COMMISSION

### Performance Review Board Appointment of Members

**AGENCY:** Equal Employment Opportunity Commission.

**ACTION:** Notice.

**SUMMARY:** This notice announces the appointment of those individuals who have been selected to serve as members of the Performance Review Board (PRB). The PRB reviews and makes recommendations concerning proposed performance appraisals, ratings, bonuses, pay adjustments, and other appropriate personnel actions for incumbents of Senior Level and Senior Executive Service positions at the EEOC.

**DATES:** Effective November 1, 2025.

**FOR FURTHER INFORMATION CONTACT:**

Jennifer Blank, Director, at (202) 921–3090 or [jennifer.blank@eoc.gov](mailto:jennifer.blank@eoc.gov), Recruitment and Executive Resources Division, Office of the Chief Human Capital Officer, U.S. Equal Employment Opportunity Commission. Requests for this document in an alternative format should be made to the EEOC's Office of Communications and Legislative Affairs at (202) 921–3191 (voice), 1–800–669–6820 (TTY), or 1–844–234–5122 (ASL video phone).

**SUPPLEMENTARY INFORMATION:** In accordance with 5 U.S.C. 4314(c)(4), the names and position titles of the EEOC PRB members are set forth below:

Christine Park-Gonzalez (Chair),  
 Director, Los Angeles District  
 Thomas Colclough, Director, Office of  
 Field Programs  
 Gregory Gochanour, Regional Attorney  
 Marcus Keegan, Regional Attorney  
 Elisa Krobot, Chief Financial Officer  
 Raymond Peeler, Associate Legal  
 Counsel  
 Amanda Smith, Director, Office of  
 Communications and Legislative  
 Affairs  
 Kimberly Essary, Associate Legal  
 Counsel (Alternate)  
 Lisa Morelli, Director, Field  
 Management Programs (Alternate)

**Jennifer Blank,**

*Director, Recruitment and Executive Resources Division, Office of the Chief Human Capital Officer.*

[FR Doc. 2025–18035 Filed 9–17–25; 8:45 am]

**BILLING CODE 6570–01–P**

## FEDERAL RESERVE SYSTEM

### Change in Bank Control Notices; Acquisitions of Shares of a Bank or Bank Holding Company

The notificants listed below have applied under the Change in Bank Control Act (Act) (12 U.S.C. 1817(j)) and § 225.41 of the Board's Regulation Y (12 CFR 225.41) to acquire shares of a bank or bank holding company. The factors

that are considered in acting on the applications are set forth in paragraph 7 of the Act (12 U.S.C. 1817(j)(7)).

The public portions of the applications listed below, as well as other related filings required by the Board, if any, are available for immediate inspection at the Federal Reserve Bank(s) indicated below and at the offices of the Board of Governors. This information may also be obtained on an expedited basis, upon request, by contacting the appropriate Federal Reserve Bank and from the Board's Freedom of Information Office at <https://www.federalreserve.gov/foia/request.htm>. Interested persons may express their views in writing on the standards enumerated in paragraph 7 of the Act.

Comments received are subject to public disclosure. In general, comments received will be made available without change and will not be modified to remove personal or business information including confidential, contact, or other identifying information. Comments should not include any information such as confidential information that would not be appropriate for public disclosure.

Comments regarding each of these applications must be received at the Reserve Bank indicated or the offices of the Board of Governors, Ann E. Misback, Secretary of the Board, 20th Street and Constitution Avenue NW, Washington, DC 20551-0001, not later than October 3, 2025.

*A. Federal Reserve Bank of Chicago* (Colette A. Fried, Assistant Vice President) 230 South LaSalle Street, Chicago, Illinois 60690-1414.

Comments can also be sent electronically to

[Comments.applications@chi.frb.org](mailto:Comments.applications@chi.frb.org):

1. *Richard A. Griffin, Dysart, Iowa*; to join the Griffin Family Group, a group acting in concert, to acquire voting shares of Dysart Bancshares, Inc., and thereby indirectly acquire voting shares of Dysart State Bank, both of Dysart, Iowa.

Board of Governors of the Federal Reserve System.

**Michele Taylor Fennell,**

*Associate Secretary of the Board.*

[FR Doc. 2025-18084 Filed 9-17-25; 8:45 am]

**BILLING CODE P**

## DEPARTMENT OF HEALTH AND HUMAN SERVICES

### Food and Drug Administration

[Docket No. FDA-2025-N-3406]

#### Fee Rate for Using a Priority Review Voucher in Fiscal Year 2026

**AGENCY:** Food and Drug Administration, HHS.

**ACTION:** Notice.

**SUMMARY:** The Food and Drug Administration (FDA or the Agency) is announcing the fee rate for using a priority review voucher for fiscal year (FY) 2026. The Federal Food, Drug, and Cosmetic Act (FD&C Act), as amended, authorizes FDA to determine and collect priority review user fees for certain applications for review of human drug or biological products when those applications use a tropical disease, rare pediatric disease, or material threat medical countermeasure (MCM) priority review voucher. These vouchers are awarded to the sponsors of tropical disease, rare pediatric disease, or material threat MCM product applications, respectively, that meet the requirements of the FD&C Act, upon FDA approval of such applications. The amount of the fee for using a priority review voucher is determined each fiscal year, based on the difference between the average cost incurred by FDA to review a human drug application designated as priority review in the previous fiscal year, and the average cost incurred in the review of an application that is not subject to priority review in the previous fiscal year. This notice establishes the FY 2026 priority review fee rate applicable to submission of eligible applications for review of human drug or biological products using a rare pediatric disease, material threat MCM, or tropical disease priority review voucher and outlines the payment procedures for such fees.

**DATES:** This rate is effective on October 1, 2025, and will remain in effect through September 30, 2026.

**FOR FURTHER INFORMATION CONTACT:** Olufunmilayo Ariyo, Office of Financial Management, Food and Drug Administration, 10903 New Hampshire Ave., Silver Spring, MD 20993, 240-402-4989; or the User Fees Support Staff at [UFSS@fda.hhs.gov](mailto:UFSS@fda.hhs.gov).

**SUPPLEMENTARY INFORMATION:**

#### I. Background

##### *A. Establishment of the Tropical Disease Priority Review Voucher*

Section 1102 of the Food and Drug Administration Amendments Act of

2007 (Pub. L. 110-85) added section 524 to the FD&C Act (21 U.S.C. 360n). In section 524 of the FD&C Act, Congress encouraged development of new human drug and biological products for prevention and treatment of tropical diseases by offering additional incentives for obtaining FDA approval of such products. Under section 524 of the FD&C Act, the sponsor of an eligible human drug application for a tropical disease (as defined in section 524(a)(3) of the FD&C Act) shall receive a priority review voucher upon approval of the tropical disease product application (as defined in section 524(a)(4) of the FD&C Act).

##### *B. Establishment of the Rare Pediatric Disease Priority Review Voucher*

Section 908 of the Food and Drug Administration Safety and Innovation Act (Pub. L. 112-144) added section 529 of the FD&C Act (21 U.S.C. 360ff). In section 529 of the FD&C Act, Congress encouraged development of new human drugs and biological products for prevention and treatment of certain rare pediatric diseases by offering additional incentives for obtaining FDA approval of such products. Under section 529 of the FD&C Act, the sponsor of an eligible human drug application for a rare pediatric disease (as defined in section 529(a)(3) of the FD&C Act) shall receive a priority review voucher upon approval of the rare pediatric disease product application (as defined in section 529(a)(4) of the FD&C Act).<sup>1</sup>

##### *C. Establishment of the Material Threat MCM Priority Review Voucher*

Section 3086 of the 21st Century Cures Act (Pub. L. 114-255) added section 565A to the FD&C Act (21 U.S.C. 360bbb-4a). In section 565A of the FD&C Act, Congress encouraged development of material threat MCMs by offering additional incentives for obtaining FDA approval of such products. Under section 565A of the FD&C Act, the sponsor of an eligible material threat MCM application (as defined in section 565A(a)(4) of the FD&C Act) shall receive a priority

<sup>1</sup> The FD&C Act includes a sunset of authority to award rare pediatric disease priority review vouchers. Section 529(b)(5) of the FD&C Act provides that after December 20, 2024, FDA may not award any rare pediatric disease priority review vouchers unless a rare pediatric disease product application: (1) is for a drug that, not later than December 20, 2024, is designated under section 529(d) of the FD&C Act as a drug for a rare pediatric disease, and (2) is, not later than September 30, 2026, approved under section 505(b)(1) of the FD&C Act or section 351(a) of the PHS Act. This limit of FDA's authority to award rare pediatric disease priority review vouchers does not affect the ability to use rare pediatric disease priority review vouchers issued by FDA.